In a groundbreaking initiative, Mali has become the first country globally to adopt a hybrid malaria vaccination approach, marking a significant advancement in the fight against one of Africa’s deadliest diseases. This innovative strategy combines routine immunization with seasonal vaccination to maximize protection for children most at risk.
On World Malaria Day, the Ministry of Health and Social Development of Mali, in collaboration with Gavi, UNICEF, and the World Health Organization (WHO), launched this pioneering method targeting children aged five to 36 months. The hybrid approach delivers the first three doses year-round based on age, followed by seasonal doses in May or June—just before the peak transmission season—when malaria cases surge.
why Mali’s hybrid malaria vaccine approach stands out
Malaria transmission in Mali is highly seasonal, with the majority of cases occurring between July and December. The hybrid strategy ensures that children receive optimal protection when they need it most. Evidence from Mali-based clinical trials demonstrates that seasonal vaccination significantly boosts the vaccine’s impact by aligning peak immunity with the highest transmission periods.
The R21/Matrix-M vaccine, initially deployed in 19 priority districts across five regions—Kayes, Koulikoro, Mopti, Ségou, and Sikasso—will be rolled out with 927,800 doses available. This follows Gavi’s global malaria vaccination program, which has already supported introductions in 19 other African nations.
Mali’s malaria burden and the urgency of vaccination
According to the WHO’s 2024 World Malaria Report, Mali accounted for 3.1% of global malaria cases (8.15 million) and 2.4% of malaria-related deaths (14,328) in 2023. The country ranks among the 11 nations with the heaviest malaria burden worldwide and was one of eight where cases surged by 1.4 million between 2019 and 2023. The African Region bears 94% of global malaria cases and 95% of deaths, underscoring the urgent need for innovative solutions.
During the launch event, Colonel Assa Badiallo Touré, Mali’s Minister of Health and Social Development, emphasized the collaborative effort behind this milestone. “This achievement reflects tireless work by researchers, Gavi, the Global Fund, WHO, and UNICEF. While the RTS,S and R21 vaccines are critical tools, their success depends on scaling up vaccination programs to protect every child.”
global support and future prospects for malaria vaccines
Gavi’s Director-General, Dr. Sania Nishtar, highlighted the importance of sustained funding to ensure equitable access to malaria vaccines. “With 20 African countries now administering over 24 million doses, continued investment is vital to reach the 50 million children targeted by 2030.”
UNICEF’s Representative in Mali, Dr. Pierre Ngom, echoed this sentiment, noting that the vaccine is a long-awaited breakthrough after 35 years of research. “While no single solution exists, vaccination complements existing malaria prevention measures like insecticide-treated nets, seasonal chemoprevention, and indoor residual spraying.” UNICEF also leverages digital tools like U-Report chatbots to combat misinformation and mobilize communities.
Dr. Patrick Kabore, WHO Representative in Mali, reinforced the vaccine’s role in public health. “This is a landmark addition to malaria control tools, offering critical protection for children and reducing the disease’s devastating impact.”
how the hybrid vaccination strategy works
The hybrid approach prioritizes children under five, who account for over 75% of global malaria deaths. Unlike adults, young children lack partial immunity from repeated exposure, making them especially vulnerable. The R21/Matrix-M and RTS,S/AS01 vaccines—both WHO-prequalified and recommended—have demonstrated high efficacy in clinical trials:
- Reduction of malaria cases by over 50% in the first year post-vaccination.
- 75% reduction in malaria cases when administered seasonally in high-transmission zones.
- Targeting Plasmodium falciparum, the deadliest malaria parasite in Africa.
expanding malaria vaccination across africa
Mali’s initiative follows Uganda’s recent large-scale deployment, with 24 million doses delivered to African countries since 2023. The continent’s 20 malaria-vaccine adopters now represent over 70% of the global malaria burden. Countries like Cameroon have also reported promising results, reinforcing the vaccine’s potential.
Looking ahead, Gavi aims to scale up programs by 2030, aiming to protect an additional 50 million children with four-dose regimens, pending sufficient funding. Other nations implementing tailored strategies include:
- Nigeria: Distributing over 800,000 doses in high-prevalence states like Kebbi and Bayelsa.
- Chad: Integrating malaria vaccination into a triple campaign targeting pneumonia and diarrhea.
- Sudan and Democratic Republic of the Congo: Embedding vaccination in broader health responses.
key takeaways for parents and caregivers
The hybrid malaria vaccine strategy in Mali offers a powerful new tool to safeguard children’s health. By combining routine and seasonal doses, it ensures maximum protection during peak transmission periods. Parents are encouraged to:
- Follow local vaccination schedules to ensure children receive all recommended doses.
- Continue using preventive measures like insecticide-treated nets and indoor spraying.
- Stay informed through trusted sources to counter misinformation about malaria vaccines.
For more details on Mali’s hybrid malaria vaccination program, explore WHO’s Q&A resource: RTS,S Malaria Vaccine Insights.
